MiNK Therapeutics, Inc. Investing Cash Flow
MiNK Therapeutics, Inc. (INKT) reported Investing Cash Flow of -$73.56 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2025-03-18
- MiNK Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2023-12-31 was $0.00.
- MiNK Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2023-09-30 was -$23.04K.
- MiNK Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2023-06-30 was -$37.02K.
- MiNK Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2023-03-31 was -$13.50K.
- MiNK Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$73.56K.
- MiNK Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$250.05K.
- MiNK Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2021 was -$248.98K.
- MiNK Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2020 was -$95.21K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$23.04K derived: sum of 2 quarters · filed 2025-03-18 | -$60.06K derived: sum of 3 quarters · filed 2025-03-18 | -$73.56K 10-K · filed 2025-03-18 |
| 2023-09-30 | -$23.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$60.06K derived: sum of 2 quarters · filed 2024-11-14 | -$73.56K 10-Q · filed 2024-11-14 | -$201.40K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$37.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$50.52K 10-Q · filed 2024-08-13 | -$178.36K derived: sum of 3 quarters · filed 2024-08-13 | -$238.15K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$13.50K 10-Q · filed 2024-05-14 | -$141.34K derived: sum of 2 quarters · filed 2024-05-14 | -$201.13K derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$127.84K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$187.63K derived: sum of 2 quarters · filed 2024-03-21 | -$250.05K 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$59.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$122.21K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | -$62.41K 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $277.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$111.54K derived: sum of 2 quarters · filed 2023-03-24 | -$209.46K derived: sum of 3 quarters · filed 2023-03-24 | -$248.98K 10-K · filed 2023-03-24 |
| 2021-09-30 | -$111.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$209.74K derived: sum of 2 quarters · filed 2022-11-03 | -$249.26K 10-Q · filed 2022-11-03 | -$249.26K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$97.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$137.44K 10-Q · filed 2022-08-15 | -$137.44K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$39.52K 10-Q · filed 2022-05-13 | -$39.52K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$95.21K 10-K · filed 2022-03-18 | ||
| 2020-09-30 | -$95.21K 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |